Log In
BCIQ
Print this Print this
 

trilaciclib (G1T28) (formerly IV G1T28-1)

  Manage Alerts
Collapse Summary General Information
Company G1 Therapeutics Inc.
DescriptionIV formulation of a selective inhibitor of cyclin dependent kinase 4 (CDK4) and CDK6
Molecular Target Cyclin dependent kinase 4 (CDK4) ; Cyclin dependent kinase 6 (CDK6)
Mechanism of ActionCyclin dependent kinase 4 (CDK4) inhibitor; Cyclin dependent kinase 6 (CDK6) inhibitor
Therapeutic ModalitySmall molecule

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
Get a free BioCentury trial today